Chemical Structure : Enasidenib
CAS No.: 1446502-11-9
Catalog No.: PC-45529Not For Human Use, Lab Use Only.
Enasidenib (AG-221, CC-90007) is an orally available, selective, potent inhibitor of mutant IDH2 with IC50s of 100-400 nM for IDH2R140Q homodimer, IDH2R172K homodimer and IDH2WT/R140Q, IDH2WT/R172K.
Packing | Price | Stock | Quantity |
---|---|---|---|
10 mg | $98 | In stock | |
25 mg | $158 | In stock | |
50 mg | $248 | In stock | |
100 mg | $398 | In stock | |
200 mg | Get quote | ||
1 g | Get quote |
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
Enasidenib (AG-221, CC-90007) is an orally available, selective, potent inhibitor of mutant IDH2 with IC50s of 100-400 nM for IDH2R140Q homodimer, IDH2R172K homodimer and IDH2WT/R140Q, IDH2WT/R172K.
Enasidenib (AG-221, CC-90007) is less potent for IDH2WT homodimer and IDH1WT homodimer.
Enasidenib (AG-221, CC-90007) suppresses 2HG production and induces cellular differentiation in primary human IDH2 mutation-positive AML cells ex vivo and in xenograft mouse models.
M.Wt | 473.375 | |
Formula | C19H17F6N7O | |
Appearance | Solid | |
Storage |
|
|
Solubility |
10 mM in DMSO |
|
Chemical Name/SMILES |
2-Propanol, 2-methyl-1-[[4-[6-(trifluoromethyl)-2-pyridinyl]-6-[[2-(trifluoromethyl)-4-pyridinyl]amino]-1,3,5-triazin-2-yl]amino]- |
1. Yen K, et al. Cancer Discov. 2017 May;7(5):478-493.
2. Kats LM, et al. Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.84.
3. Shih AH, et al. Cancer Discov. 2017 May;7(5):494-505.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright